<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>E-cadherin, encoded by the CDH1 gene, involves in invasion and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>CDH1 -C160A polymorphism was shown to contribute to genetic susceptibility to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>However, the results from different studies remain controversial </plain></SENT>
<SENT sid="3" pm="."><plain>This study was conducted to further explore the association between CDH1 -C160A genetic polymorphism and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> susceptibility by means of a meta-analysis </plain></SENT>
<SENT sid="4" pm="."><plain>A comprehensive literature search was conducted to identify <z:hpo ids='HP_0000001'>all</z:hpo> case-control studies of CDH1 -C160A polymorphism and risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>A total of nine eligible studies, including 7954 CRC cases and 7369 controls, were identified to the meta-analysis </plain></SENT>
<SENT sid="6" pm="."><plain>On the whole, the meta-analysis indicated that CDH1 -C160A genetic polymorphism could reduce the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> under AA versus CC contrast (odds ratio [OR]=0.86, 95% confidence interval [CI]=0.75-0.98, p(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>)=0.11), recessive model (OR=0.88, 95% CI=0.77-0.99, p(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>)=0.23), dominant model (OR=0.92, 95% CI=0.87-0.99, p(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>)=0.11), and allele A versus allele C contrast (OR=0.93, 95% CI=0.88-0.98, p(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>)=0.26) </plain></SENT>
<SENT sid="7" pm="."><plain>A conclusion could be drawn from the research that CDH1 -C160A polymorphism provides a possible protection against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, which is especially evident in Caucasian and hospital populations </plain></SENT>
</text></document>